Short Interest in ZIOPHARM Oncology Inc. (ZIOP) Declines By 3.7%
ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) was the recipient of a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 34,006,567 shares, a drop of 3.7% from the February 15th total of 35,317,685 shares. Based on an average daily volume of 1,310,304 shares, the short-interest ratio is currently 26.0 days. Approximately 29.4% of the shares of the stock are sold short.
Shares of ZIOPHARM Oncology (NASDAQ:ZIOP) opened at $4.34 on Monday. The stock has a market cap of $616.12, a PE ratio of -8.04 and a beta of 1.42. ZIOPHARM Oncology has a 52-week low of $3.33 and a 52-week high of $7.88.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings results on Thursday, March 1st. The biotechnology company reported ($0.13) EPS for the quarter, meeting the consensus estimate of ($0.13). The business had revenue of $1.60 million during the quarter, compared to the consensus estimate of $1.59 million. During the same quarter in the prior year, the firm posted ($0.11) EPS. The company’s revenue for the quarter was up .0% compared to the same quarter last year. analysts anticipate that ZIOPHARM Oncology will post -0.58 EPS for the current year.
Several brokerages have recently commented on ZIOP. Zacks Investment Research upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. BidaskClub cut shares of ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Thursday, January 11th. HC Wainwright set a $10.00 price objective on shares of ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Monday, March 5th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $7.50.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.